Department of Bioinformatics, Center of Medical Biotechnology, University of Duisburg-Essen, Universitaetsstr, 2, 45117 Essen, Germany.
BioData Min. 2011 Nov 14;4:26. doi: 10.1186/1756-0381-4-26.
Maturation inhibitors such as Bevirimat are a new class of antiretroviral drugs that hamper the cleavage of HIV-1 proteins into their functional active forms. They bind to these preproteins and inhibit their cleavage by the HIV-1 protease, resulting in non-functional virus particles. Nevertheless, there exist mutations in this region leading to resistance against Bevirimat. Highly specific and accurate tools to predict resistance to maturation inhibitors can help to identify patients, who might benefit from the usage of these new drugs.
We tested several methods to improve Bevirimat resistance prediction in HIV-1. It turned out that combining structural and sequence-based information in classifier ensembles led to accurate and reliable predictions. Moreover, we were able to identify the most crucial regions for Bevirimat resistance computationally, which are in line with experimental results from other studies.
Our analysis demonstrated the use of machine learning techniques to predict HIV-1 resistance against maturation inhibitors such as Bevirimat. New maturation inhibitors are already under development and might enlarge the arsenal of antiretroviral drugs in the future. Thus, accurate prediction tools are very useful to enable a personalized therapy.
成熟抑制剂,如贝维利姆,是一类新型抗逆转录病毒药物,可阻碍 HIV-1 蛋白切割成具有功能的活性形式。它们与这些前体蛋白结合,并抑制 HIV-1 蛋白酶对其的切割,导致无功能的病毒颗粒。然而,该区域存在导致对贝维利姆产生耐药性的突变。高度特异和准确的工具来预测对成熟抑制剂的耐药性有助于识别可能受益于这些新药的患者。
我们测试了几种方法来改进 HIV-1 中贝维利姆耐药性的预测。事实证明,将结构和基于序列的信息组合在分类器集合中可导致准确和可靠的预测。此外,我们能够在计算上确定对贝维利姆耐药性至关重要的区域,这与其他研究的实验结果一致。
我们的分析证明了机器学习技术在预测 HIV-1 对成熟抑制剂(如贝维利姆)的耐药性方面的应用。新的成熟抑制剂正在开发中,将来可能会扩大抗逆转录病毒药物的武器库。因此,准确的预测工具对于实现个体化治疗非常有用。